Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 186 entries
Sorted by: Best Match Show Resources per page
Web alert. The chemistry of metabolic and toxicological processes.

Current opinion in drug discovery & development

Cavalla D.
PMID: 11727319
Curr Opin Drug Discov Devel. 2001 Jan;4(1):25-6.

No abstract available.

Cite
Cavalla D. Web alert. The chemistry of metabolic and toxicological processes. Curr Opin Drug Discov Devel. 2001;4(1):25-6
Cavalla, D. (2001). Web alert. The chemistry of metabolic and toxicological processes. Current opinion in drug discovery & development, 4(1), 25-6.
Cavalla, D. "Web alert. The chemistry of metabolic and toxicological processes." Current opinion in drug discovery & development vol. 4,1 (2001): 25-6.
Cavalla D. Web alert. The chemistry of metabolic and toxicological processes. Curr Opin Drug Discov Devel. 2001 Jan;4(1):25-6. PMID: 11727319.
Copy Download .nbib Format: NLM
Structure-based design of enzyme inhibitors and receptor ligands.

Current opinion in drug discovery & development

Kubinyi H.
PMID: 19649784
Curr Opin Drug Discov Devel. 1998 Jul;1(1):4-15.

With the ongoing progress in protein crystallography and NMR, structure-based drug design is adopting increasing importance in the search for new drugs. Modeling starts from the 3D structure of a target protein in order to construct molecules which are...

Cite
Kubinyi H. Structure-based design of enzyme inhibitors and receptor ligands. Curr Opin Drug Discov Devel. 1998;1(1):4-15
Kubinyi, H. (1998). Structure-based design of enzyme inhibitors and receptor ligands. Current opinion in drug discovery & development, 1(1), 4-15.
Kubinyi, H. "Structure-based design of enzyme inhibitors and receptor ligands." Current opinion in drug discovery & development vol. 1,1 (1998): 4-15.
Kubinyi H. Structure-based design of enzyme inhibitors and receptor ligands. Curr Opin Drug Discov Devel. 1998 Jul;1(1):4-15. PMID: 19649784.
Copy Download .nbib Format: NLM
The role of chemical engineering in pharmaceutical chemical process development.

Current opinion in drug discovery & development

Landau RN, Blacklock TJ, Girgis MJ, Tedesco A.
PMID: 19649800
Curr Opin Drug Discov Devel. 1998 Nov;1(3):257-63.

The task of chemical process development in the pharmaceutical industry has grown into a multidisciplinary endeavor requiring years to complete. Increased competition in the pharmaceutical Additionally, the ever-tightening regulatory environment further compromises the business objective (ultimately, profits). This has...

Cite
Landau RN, Blacklock TJ, Girgis MJ, et al. The role of chemical engineering in pharmaceutical chemical process development. Curr Opin Drug Discov Devel. 1998;1(3):257-63
Landau, R. N., Blacklock, T. J., Girgis, M. J., & Tedesco, A. (1998). The role of chemical engineering in pharmaceutical chemical process development. Current opinion in drug discovery & development, 1(3), 257-63.
Landau, R N, et al. "The role of chemical engineering in pharmaceutical chemical process development." Current opinion in drug discovery & development vol. 1,3 (1998): 257-63.
Landau RN, Blacklock TJ, Girgis MJ, Tedesco A. The role of chemical engineering in pharmaceutical chemical process development. Curr Opin Drug Discov Devel. 1998 Nov;1(3):257-63. PMID: 19649800.
Copy Download .nbib Format: NLM
Development of an asymmetric Michael addition in a practical synthesis of ABT-546.

Current opinion in drug discovery & development

Barnes DM.
PMID: 19649909
Curr Opin Drug Discov Devel. 2000 Nov;3(6):818-24.

ABT-546 is a selective antagonist of the endothelin A receptor. This review will present the development of a scalable synthesis of ABT-546 from early discovery to the route that was employed to prepare sufficient material for toxicology and phase...

Cite
Barnes DM. Development of an asymmetric Michael addition in a practical synthesis of ABT-546. Curr Opin Drug Discov Devel. 2000;3(6):818-24
Barnes, D. M. (2000). Development of an asymmetric Michael addition in a practical synthesis of ABT-546. Current opinion in drug discovery & development, 3(6), 818-24.
Barnes, D M. "Development of an asymmetric Michael addition in a practical synthesis of ABT-546." Current opinion in drug discovery & development vol. 3,6 (2000): 818-24.
Barnes DM. Development of an asymmetric Michael addition in a practical synthesis of ABT-546. Curr Opin Drug Discov Devel. 2000 Nov;3(6):818-24. PMID: 19649909.
Copy Download .nbib Format: NLM
New mechanistic aspects of the asymmetric homogeneous hydrogenation of alkenes.

Current opinion in drug discovery & development

Brown JM, Giernoth R.
PMID: 19649910
Curr Opin Drug Discov Devel. 2000 Nov;3(6):825-32.

Progress in homogeneous catalysis depends upon an understanding of the reaction mechanism; in asymmetric catalysis this entails an insight into the origins of enantioselectivity. Significant advances have been made in the area of alkene reduction catalyzed by rhodium or...

Cite
Brown JM, Giernoth R. New mechanistic aspects of the asymmetric homogeneous hydrogenation of alkenes. Curr Opin Drug Discov Devel. 2000;3(6):825-32
Brown, J. M., & Giernoth, R. (2000). New mechanistic aspects of the asymmetric homogeneous hydrogenation of alkenes. Current opinion in drug discovery & development, 3(6), 825-32.
Brown, J M, and Giernoth, R. "New mechanistic aspects of the asymmetric homogeneous hydrogenation of alkenes." Current opinion in drug discovery & development vol. 3,6 (2000): 825-32.
Brown JM, Giernoth R. New mechanistic aspects of the asymmetric homogeneous hydrogenation of alkenes. Curr Opin Drug Discov Devel. 2000 Nov;3(6):825-32. PMID: 19649910.
Copy Download .nbib Format: NLM
Novel technology to improve pharmaceutical productivity.

Current opinion in drug discovery & development

Krebs R.
PMID: 19649952
Curr Opin Drug Discov Devel. 1999 May;2(3):239-43.

A review of the literature published from late 1997 to the end of 1998 reveals a shift in paradigm of the discovery process and hence the productivity of pharmaceutical companies. Key factors are combined use in high-throughput screening systems....

Cite
Krebs R. Novel technology to improve pharmaceutical productivity. Curr Opin Drug Discov Devel. 1999;2(3):239-43
Krebs, R. (1999). Novel technology to improve pharmaceutical productivity. Current opinion in drug discovery & development, 2(3), 239-43.
Krebs, R. "Novel technology to improve pharmaceutical productivity." Current opinion in drug discovery & development vol. 2,3 (1999): 239-43.
Krebs R. Novel technology to improve pharmaceutical productivity. Curr Opin Drug Discov Devel. 1999 May;2(3):239-43. PMID: 19649952.
Copy Download .nbib Format: NLM
The design and molecular modeling of CNS drugs.

Current opinion in drug discovery & development

George A.
PMID: 19649956
Curr Opin Drug Discov Devel. 1999 Jul;2(4):286-92.

The medical need for new drugs to treat CNS disorders and their commercial potential is not in question, however, CNS drugs may require different pharmacokinetic and pharmacological profiles to peripherally acting compounds. The role of molecular modeling in both...

Cite
George A. The design and molecular modeling of CNS drugs. Curr Opin Drug Discov Devel. 1999;2(4):286-92
George, A. (1999). The design and molecular modeling of CNS drugs. Current opinion in drug discovery & development, 2(4), 286-92.
George, A. "The design and molecular modeling of CNS drugs." Current opinion in drug discovery & development vol. 2,4 (1999): 286-92.
George A. The design and molecular modeling of CNS drugs. Curr Opin Drug Discov Devel. 1999 Jul;2(4):286-92. PMID: 19649956.
Copy Download .nbib Format: NLM
Structure-activity relationships and pharmacological profiles of new 5-HT(1) receptor agonists as antimigraine agents.

Current opinion in drug discovery & development

Perez M, John GW.
PMID: 19649958
Curr Opin Drug Discov Devel. 1999 Jul;2(4):304-10.

The design of new generation drugs acting as 5-HT1 receptor agonists, in the field of acute treatment of migraine, is still very active. The reason is the need for safer medicines with improved response rates and a reduced rate...

Cite
Perez M, John GW. Structure-activity relationships and pharmacological profiles of new 5-HT(1) receptor agonists as antimigraine agents. Curr Opin Drug Discov Devel. 1999;2(4):304-10
Perez, M., & John, G. W. (1999). Structure-activity relationships and pharmacological profiles of new 5-HT(1) receptor agonists as antimigraine agents. Current opinion in drug discovery & development, 2(4), 304-10.
Perez, M, and John, G W. "Structure-activity relationships and pharmacological profiles of new 5-HT(1) receptor agonists as antimigraine agents." Current opinion in drug discovery & development vol. 2,4 (1999): 304-10.
Perez M, John GW. Structure-activity relationships and pharmacological profiles of new 5-HT(1) receptor agonists as antimigraine agents. Curr Opin Drug Discov Devel. 1999 Jul;2(4):304-10. PMID: 19649958.
Copy Download .nbib Format: NLM
Recent advances in traceless linkers.

Current opinion in drug discovery & development

Reitz AB.
PMID: 19649964
Curr Opin Drug Discov Devel. 1999 Jul;2(4):358-64.

The use of solid-phase organic synthesis for the preparation of small molecule compound libraries has been the driving force behind the development of new linkers and reaction technologies. Traceless linkers afford targets in which it is not readily apparent...

Cite
Reitz AB. Recent advances in traceless linkers. Curr Opin Drug Discov Devel. 1999;2(4):358-64
Reitz, A. B. (1999). Recent advances in traceless linkers. Current opinion in drug discovery & development, 2(4), 358-64.
Reitz, A B. "Recent advances in traceless linkers." Current opinion in drug discovery & development vol. 2,4 (1999): 358-64.
Reitz AB. Recent advances in traceless linkers. Curr Opin Drug Discov Devel. 1999 Jul;2(4):358-64. PMID: 19649964.
Copy Download .nbib Format: NLM
Recent developments in solid- and solution-phase methods for generating carbohydrate libraries.

Current opinion in drug discovery & development

Sofia MJ, Silva DJ.
PMID: 19649965
Curr Opin Drug Discov Devel. 1999 Jul;2(4):365-76.

Carbohydrates and glycoconjugates have attracted a great deal of attention in recent years because of the key roles they play in biological processes. The development of carbohydrate-based libraries is a crucial step towards investigating the details of carbohydrate-mediated interactions,...

Cite
Sofia MJ, Silva DJ. Recent developments in solid- and solution-phase methods for generating carbohydrate libraries. Curr Opin Drug Discov Devel. 1999;2(4):365-76
Sofia, M. J., & Silva, D. J. (1999). Recent developments in solid- and solution-phase methods for generating carbohydrate libraries. Current opinion in drug discovery & development, 2(4), 365-76.
Sofia, M J, and Silva, D J. "Recent developments in solid- and solution-phase methods for generating carbohydrate libraries." Current opinion in drug discovery & development vol. 2,4 (1999): 365-76.
Sofia MJ, Silva DJ. Recent developments in solid- and solution-phase methods for generating carbohydrate libraries. Curr Opin Drug Discov Devel. 1999 Jul;2(4):365-76. PMID: 19649965.
Copy Download .nbib Format: NLM
Developments in solution-phase combinatorial chemistry.

Current opinion in drug discovery & development

Suto MJ.
PMID: 19649966
Curr Opin Drug Discov Devel. 1999 Jul;2(4):377-84.

The use of solution-phase parallel synthesis as a means of producing libraries of compounds for lead discovery and optimization has increased steadily. More emphasis has been placed on the development of techniques that are applicable across a range of...

Cite
Suto MJ. Developments in solution-phase combinatorial chemistry. Curr Opin Drug Discov Devel. 1999;2(4):377-84
Suto, M. J. (1999). Developments in solution-phase combinatorial chemistry. Current opinion in drug discovery & development, 2(4), 377-84.
Suto, M J. "Developments in solution-phase combinatorial chemistry." Current opinion in drug discovery & development vol. 2,4 (1999): 377-84.
Suto MJ. Developments in solution-phase combinatorial chemistry. Curr Opin Drug Discov Devel. 1999 Jul;2(4):377-84. PMID: 19649966.
Copy Download .nbib Format: NLM
The role of mass spectrometry in the drug discovery process.

Current opinion in drug discovery & development

Pramanik BN, Bartner PL, Chen G.
PMID: 19649969
Curr Opin Drug Discov Devel. 1999 Jul;2(4):401-17.

The structure characterization of biologically-active organic compounds, developed from synthetic and natural sources, is an integral part of the drug discovery effort to identify novel therapeutic agents. Mass spectrometric methods (electrospray ionization, matrix-assisted laser desorption/ionization, fast atom bombardment, electron...

Cite
Pramanik BN, Bartner PL, Chen G. The role of mass spectrometry in the drug discovery process. Curr Opin Drug Discov Devel. 1999;2(4):401-17
Pramanik, B. N., Bartner, P. L., & Chen, G. (1999). The role of mass spectrometry in the drug discovery process. Current opinion in drug discovery & development, 2(4), 401-17.
Pramanik, B N, et al. "The role of mass spectrometry in the drug discovery process." Current opinion in drug discovery & development vol. 2,4 (1999): 401-17.
Pramanik BN, Bartner PL, Chen G. The role of mass spectrometry in the drug discovery process. Curr Opin Drug Discov Devel. 1999 Jul;2(4):401-17. PMID: 19649969.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 186 entries